Literature DB >> 14628187

Acute effects of estrogen upon methamphetamine induced neurotoxicity of the nigrostriatal dopaminergic system.

T M Gajjar1, L I Anderson, D E Dluzen.   

Abstract

Estrogen acts as a neuroprotectant of the nigrostriatal dopaminergic system when given chronically to female mice prior to Methamphetamine (MA) insult. In this report, we tested the acute effects of Estradiol Benzoate (EB-10 microg in Oil) in ovariectomized CD-1 mice to function as a neuroprotectant when administered prior to (Experiment 1) or after (Experiment 2) MA treatment. Striatal dopamine (DA) concentrations and DOPAC/DA ratios were measured to assess the neuroprotective effects of EB. In Experiment 1, we observed that EB exerted a neuroprotective effect upon striatal dopamine concentrations when administered at 24 and 12, but not at 0.5, hours prior to MA injection and upon DOPAC/DA ratios when administered at 24, 12 and 0.5 hours prior to MA. In Experiment 2, no evidence for estrogen to protect the striatum from MA insult was obtained when EB was administered at 15, 30, 60 or 120 minutes after MA. These results show that EB can act as a modulator of MA-induced nigrostriatal dopaminergic neurotoxicity suggestive of a neuroprotectant, when administered within 0.5 hour of MA insult as assessed by measures of DOPAC/DA, but fails to prevent depletion of DA when given after MA insult. The data suggest that estrogen may exert this rapid neuroprotective effect through a non-genomic mechanism.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14628187     DOI: 10.1007/s00702-003-0045-3

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  18 in total

1.  Risk factors for Parkinson's disease may differ in men and women: an exploratory study.

Authors:  Rodolfo Savica; Brandon R Grossardt; James H Bower; J Eric Ahlskog; Walter A Rocca
Journal:  Horm Behav       Date:  2012-06-08       Impact factor: 3.587

2.  The impact of clinical and demographic variables on cognitive performance in methamphetamine-dependent individuals in rural South Carolina.

Authors:  Kimber L Price; Stacia M DeSantis; Annie N Simpson; Bryan K Tolliver; Aimee L McRae-Clark; Michael E Saladin; Nathaniel L Baker; Mark T Wagner; Kathleen T Brady
Journal:  Am J Addict       Date:  2011-07-18

3.  Effects of age, gender, and gonadectomy on neurochemistry and behavior in animal models of Parkinson's disease.

Authors:  Andrea Tamás; Andrea Lubics; István Lengvári; Dóra Reglodi
Journal:  Endocrine       Date:  2006-04       Impact factor: 3.633

Review 4.  Caveolin proteins and estrogen signaling in the brain.

Authors:  Jessie I Luoma; Marissa I Boulware; Paul G Mermelstein
Journal:  Mol Cell Endocrinol       Date:  2008-04-22       Impact factor: 4.102

5.  Gender, brain-derived neurotrophic factor Val66Met, and frequency of methamphetamine use.

Authors:  Keith G Heinzerling; Steven Shoptaw
Journal:  Gend Med       Date:  2012-03-23

6.  Female reproductive factors, menopausal hormone use, and Parkinson's disease.

Authors:  Rui Liu; Donna Baird; Yikyung Park; Neal D Freedman; Xuemei Huang; Albert Hollenbeck; Aaron Blair; Honglei Chen
Journal:  Mov Disord       Date:  2013-12-18       Impact factor: 10.338

7.  STX, a novel nonsteroidal estrogenic compound, induces rapid action in primate GnRH neuronal calcium dynamics and peptide release.

Authors:  B P Kenealy; K L Keen; O K Rønnekleiv; E Terasawa
Journal:  Endocrinology       Date:  2011-05-31       Impact factor: 4.736

8.  Variants in estrogen-related genes and risk of Parkinson's disease.

Authors:  Sun Ju Chung; Sebastian M Armasu; Joanna M Biernacka; Timothy G Lesnick; David N Rider; Julie M Cunningham; Demetrius M Maraganore
Journal:  Mov Disord       Date:  2011-04-05       Impact factor: 10.338

9.  Gender differences in Parkinson's disease.

Authors:  Charlotte A Haaxma; Bastiaan R Bloem; George F Borm; Wim J G Oyen; Klaus L Leenders; Silvia Eshuis; Jan Booij; Dean E Dluzen; Martin W I M Horstink
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-11-10       Impact factor: 10.154

10.  Does glitazone treatment have a role on the prevention of Parkinson's disease in adult diabetic population? A systematic review.

Authors:  Jesús D Meléndez-Flores; Juan Manuel Millán-Alanís; Adrián González-Martínez; Neri Alejandro Álvarez-Villalobos; Ingrid Estrada-Bellmann
Journal:  Metab Brain Dis       Date:  2020-05-04       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.